Medicap Joint Relief- II
Natural health product licensed in Canada
- Other names
- CHOLLIMA, POSAFLEX-F
- Licence holder
- Biowell Laboratories
- NPN or DIN-HM
- 80081357
- Status
- Active licence
- Licence date
- 21 November 2017
- Revision date
- 25 June 2019
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Sulfate de chondroïtine Source : Sulfate de chondroïtine | 100 mg | Not calculated |
| (1E,6E)-1,7-Bis(4-hydroxy-3-méthoxyphényl)-1,6-heptadiène-3,5-dione Source : Curcumine | 50 mg | Not calculated |
| Sulfone de diméthyl Source : Sulfone de diméthyl | 100 mg | Not calculated |
| Sulfate de 2-Amino-2-désoxy-D-glucose Source : Sulfate de glucosamine chlorure de potassium | 750 mg | Not calculated |
| Collagène hydrolysé Source : Collagène hydrolysé | 50 mg | Not calculated |
Non-medicinal ingredients
Croscarmellose de sodium, Stéarate de magnésium, Phosphate dicalcique, Dioxyde de silicium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Comprimé | minimum: 1 Tous les jours ; maximum: 2 Tous les jours |
Uses authorised in Canada
Helps to relieve joint pain associated with osteoarthritis (of the knee). Helps to protect against the deterioration of cartilage. A factor in maintaining healthy cartilage and/or joint health.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Some people may experience mild gastrointestinal disturbances such as diarrhoea, abdominal pain, heartburn, nausea and vomiting; in which case, discontinue use.
- Précautions et mises en garde
If you are taking antiplatelet medication or blood thinners, consult a health care practitioner prior to use. If you have gallstones or a bile duct obstruction, consult a health care practitioner prior to use. If you have stomach ulcers or excess stomach acid, consult a health care practitioner prior to use. If you are pregnant or breastfeeding, consult a health care practitioner prior to use. If symptoms worsen, consult a health care practitioner.
Source
Official Health Canada record, licence 80081357
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2019. Photograph the packaging to check whether it has changed. Photograph the packaging